|
rs1001179
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results demonstrated that the rs1001179 polymorphism was associated with an increased cancer risk in the recessive and homozygote models (TT vs. CC: OR = 1.19, P = 0.01; TT vs. CT+CC: OR = 1.19, P <0.001).
|
27449288 |
2016 |
|
rs10012
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
To derive a more precise estimation of the association between the CYP1B1 polymorphisms and cancer risk, we performed a meta-analysis to investigate the association between cancer susceptibility and CYP1B1 Leu432Val, Asn453Ser, Arg48Gly, and Ala119Ser polymorphisms.
|
25475389 |
2015 |
|
rs1005464
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Subjects carrying the AA genotype of rs1005464 had significant decreased cancer risk (age-adjusted OR = 0.44, 95% CI of 0.23-0.85) compared with those carrying the GG genotype.
|
25391427 |
2015 |
|
rs10074991
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
To sum up, PRKAA1 rs13361707 polymorphism is not participant with the increased risk of cancer, while the A allele of PRKAA1 rs10074991 revealed a significant decrease risk.
|
30340465 |
2018 |
|
rs10109984
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results showed that no significant associations with cancer risk were found in any model in terms of rs7003908, rs7830743 and rs10109984 when all studies were pooled into the meta-analysis.
|
23108991 |
2013 |
|
rs1012049
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
One additional sample showed that four SNPs were associated with risk of cancer (top SNP rs1339197 with p = 4.1 × 10<sup>-3</sup>), 12 SNPs associated with LDL-cholesterol (top SNP rs4544930 with p = 3.47 × 10<sup>-3</sup>), and eight SNPs associated with total cholesterol (top SNP rs1012049 with p = 6.09 × 10<sup>-3</sup>).
|
28987514 |
2018 |
|
rs10131
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We found that GA+AA of LIG4 rs10131 was associated with increased risk of glioma in those without family history of cancer, and the OR (95% CI) was 1.78 (1.12-2.83).
|
25973104 |
2015 |
|
rs10132552
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Certain polymorphisms within MEG3 are implicated in cancer risk (rs7158663, rs4081134 and rs11160608) or therapeutic response of cancer patients (rs10132552).
|
31326791 |
2019 |
|
rs1015213
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
To investigate if the single nucleotide polymorphisms rs3753841, rs1015213 and rs11024102, recently implicated in the development of acute primary angle closure or primary angle closure glaucoma, are associated with ocular biometric characteristics of British adults in the European Prospective Investigation of Cancer-Norfolk eye study.
|
23505305 |
2013 |
|
rs10165970
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate.
|
28177907 |
2017 |
|
rs10175368
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Interestingly when classified by lifestyle factors, no associations of genotypes were found for non-smokers and non-drinkers, whereas on the contrary, minor type at rs2567206 and rs10175368 increased and major G-C-T-G decreased risk for cancer among smokers and drinkers.
|
30133114 |
2018 |
|
rs1018379423
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data show that weak activation of the Mek/Erk pathway underpins RASopathies, but in cancer, (L597V)Braf epistatically modifies the transforming effects of driver oncogenes.
|
22892241 |
2012 |
|
rs1019340046
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our results show: (1) wild-type p53 stimulates the transcription of reporter genes with p53CON and RGC in their 5' region while most p53 mutants occurring in human cancers have lost this activity; (2) the R273H mutant retains transcriptional activity for the p53CON sequence but not RGC; (3) some mutants are temperature-sensitive for the transcriptional activity with the p53CON but not the RGC sequence; (4) p53 mutants vary in their ability to inhibit wild-type p53 transactivation but there is no difference between p53CON and RGC sequences; (5) lung cancer cells with endogenous mutant p53 proteins (M246I in H23 cells and R248L in H322 cells) retain transcriptional activity for the p53CON but not the RGC sequence.
|
8336941 |
1993 |
|
rs10203853
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
UGT1A haplotype analysis found that the T-G haplotype in UGT1A10 exon 1 (block 2: rs17864678, rs10929251) decreased cancer risk for the colon [proximal (OR = 0.28, 95% CI = 0.11–0.69) and for the distal colon (OR = 0.32, 95% CI = 0.12–0.91)], and that the C-T-G haplotype in the 3′ region flanking the UGT1A shared exons (block 11: rs7578153, rs10203853, rs6728940) increased CRC risk in males (OR = 2.56, 95% CI = 1.10–5.95).
|
24822274 |
2014 |
|
rs1024611
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data demonstrated the CCL2-2518A/G (rs1024611) polymorphism is significantly associated with risk of gynecological cancer, and the association differs by ethnicity.
|
29458367 |
2018 |
|
rs10248565
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The results elucidate the genetic etiology of lung adenocarcinoma by demonstrating that SNP rs10248565 may be a potential biomarker of cancer susceptibility.
|
24650256 |
2014 |
|
rs10272859
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
This index rs10272859 also showed significant association with the survival of HCC patients.<b>Conclusions:</b> Our findings highlight a novel locus at 7q21.13 conferring both susceptibility and prognosis to HBV-related HCC, and suggest the <i>CDK14</i> gene to be the functional target of the 7q21.13 locus.<i>Clin Cancer Res; 24(4); 906-15.©2017 AACR</i>.
|
29246937 |
2018 |
|
rs1027720509
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Irrespective of cancer status, several SNPs were found to be associated with altered serum folate concentrations, including the D919G SNP in methionine synthase (MTR), the L474F SNP in serine hydroxymethyl transferase 1 (SHMT1) and the V175M SNP in phosphatidyl ethanolamine methyltransferase (PEMT).
|
29474406 |
2018 |
|
rs1029342144
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Statistically significant associations were noted between SNPs in beta-catenin and APOE and a positive family history of cancer (beta-catenin: p=0.034, APOE: p=0.033); tumor location and a DCC SNP (p=0.038) and the P53 R72P mutation and survival (p=0.0336).
|
15523694 |
2005 |
|
rs1034528
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our meta-analysis found that rs1883965, rs1034528, and rs17036508 were correlated with increased cancer risk in the complete over-dominant model (rs1883965 GA versus GG/AA: fixed-effects OR=1.15, 95% CI 1.02-1.29; rs1034528 GC versus GG/CC: fixed-effects OR=1.30, 95% CI 1.13-1.48; rs17036508 TC versus CC/TT: fixed-effects OR=1.23, 95% CI 1.06-1.43).
|
27462867 |
2016 |
|
rs1041981
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our results showed significant associations with increased cancer risk for rs1041981 (odd ratio (OR) = 1.15, 99% confidential interval (CI) = 1.07-1.25, P < 0.0001, I(2) = 12.2%), rs2239704 (OR = 1.08, 99% CI = 1.01-1.16, P = 0.021, I(2) = 0.0%) and rs2229094 (OR = 1.28, 99% CI = 1.09-1.50, P = 0.003, I(2) = 0.0%).
|
24349304 |
2013 |
|
rs1042667
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Results showed that SOX9 rs1042667 was significant associated with increased gliomas risk after adjusted by age, gender, family history of cancer, smoking status and alcohol status (Allele C vs A: OR=1.25; 95% CI=1.11-1.40; P=1.2×10-4).
|
27589569 |
2016 |
|
rs1042821
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
The present meta-analysis identified some statistical evidence for an association between the MSH6 G39E polymorphism and risk of cancer.
|
24622885 |
2014 |
|
rs1043210477
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
No significant association of MnSOD Ala-9Val polymorphism with cancer risk was observed (AlaVal/ValVal vs. AlaAla, OR = 0.966, 95% CI = 0.754-1.239, heterogeneity (p = 0.390); Vla vs. Ala, OR = 1.038, 95% CI = 0.782-1.377, heterogeneity (p = 0.015)).
|
24037914 |
2014 |
|
rs1044129
|
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this study, four miRNA binding-site single nucleotide polymorphisms (SNPs) located in the 3' UTR of RYR3 (rs1044129), C14orf101 (rs4901706), KIAA0423 (rs1053667), and GOLGA7 (rs11337) were genotyped in non-Hodgkin lymphoma (NHL) patients to assess their relationships with cancer risk and overall survival. rs4901706, located in the 3' UTR of C14orf101, was shown to be independently related to overall survival in NHL patients by multivariate analysis (relative risk, 1.770; 95% CI, 1.046-2.996; P = 0.033).
|
24831772 |
2014 |